Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Human Genome Sciences (NasdaqNM:HGSI)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
9410 Key West Avenue
Rockville, MD 20850
Phone: (301) 309-8504
Fax: (301) 309-8512
Employees (last reported count): 720
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·Nasdaq 100
Ownership
·Insider and 5%+ Owners: 39%
·Over the last 6 months:
 · one insider buy; 2,000  shares
 · 16 insider sells; 1.43M shares
  (2.8% of insider shares)
·Institutional: 67% (110% of float)
(564 institutions)
·Net Inst. Buying: 192.0K shares
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Human Genome Sciences Inc. is a genomics and biopharmaceutical company focused on therapeutic product development and functional analysis of genes using its proprietary technology platform. The Company discovers, researches, develops and intends to commercialize novel compounds for treating and diagnosing human disease based on the identification and study of genes. The Company focuses its internal product development efforts on therapeutic proteins, antibodies, peptides and fusion proteins, and it uses collaborations for the development of gene therapy products and small molecule drugs. It has discovered a large number of genes through its genomics capabilities and has developed a rapidly evolving product pipeline based on its discoveries.
More from Market Guide: Expanded Business Description

Financial Summary
HGSI is engaged in research and development of novel proprietary pharmaceutical and diagnostic products based on the discovery and understanding of the medical utility of genes. For the six months ended 6/30/01, total revenues remained unchanged at $10.5 million. Net loss before acct. change fell 54% to $37 million. Revenues reflect continuing license fees and milestone payments. Lower loss reflects lower debt conversion expenses and higher interest income.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Compensation
PayExer

William Haseltine, Ph.D., 55
Chairman, CEO
$656K--  
Craig Rosen, Ph.D., 42
Exec. VP of R&D, Director
469K$220K
Steven Mayer, 46
Sr. VP and CFO
404K2.1M
James Davis, Ph.D., 49
Sr. VP, Gen. Counsel and Sec.
324K1.1M
Susan Bateson McKay, 45
Sr. VP of HR
--  --  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:HGSIAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$35.50 
Recent Price$44.88 
52-Week High
on 19-Oct-2000
$106.859
Beta0.66 
Daily Volume (3-month avg)3.00M
Daily Volume (10-day avg)1.98M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-49.2%
52-Week Change
relative to S&P500
-31.8%
Share-Related Items
Market Capitalization$5.72B
Shares Outstanding127.5M
Float77.8M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 6-Oct-2000
Per-Share Data
Book Value (mrq)$10.51 
Earnings (ttm)-$1.50 
Earnings (mrq)-$0.19 
Sales (ttm)$0.17 
Cash (mrq)$13.23 
Valuation Ratios
Price/Book (mrq)4.27 
Price/EarningsN/A 
Price/Sales (ttm)257.93 
Income Statements
Sales (ttm)$22.1M
EBITDA (ttm)-$251.6M
Income available to common (ttm)-$191.9M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-11.29%
Return on Equity (ttm)-17.02%
Financial Strength
Current Ratio (mrq)46.33 
Debt/Equity (mrq)0.38 
Total Cash (mrq)$1.69B
Short Interest
As of 8-Aug-2001
Shares Short6.50M
Percent of Float8.4%
Shares Short
(Prior Month)
6.94M
Short Ratio2.56 
Daily Volume2.54M
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.